Is Your Cat Eligible?
If interested in participating in this study, please fill out the Cat Diet Study Survey here to find out if your cat is eligible.
Heart disease is a very common problem in cats, with the most common form of feline heart disease being hypertrophic cardiomyopathy. Heart disease can lead to significant complications, including congestive heart failure, severe blood clotting, and even sudden death. We are always looking for promising new medications to help treat this ongoing problem. Velagliflozin is a drug that has been shown to improve quality of life for human patients with heart failure. In the present study, we are looking for improvements in clinical signs and diagnostic measurements that occur with velagliflozin treatment in cats with heart failure. We are also looking to monitor for and describe any significant side effects associated with velagliflozin administration.
Participation in the study will include free echocardiogram and cardiac blood parameter testing at the initial and recheck appointments. Additional costs covered include the 6 month supply of velagliflozin and any appointment fees associated with study-related recheck appointments.
Echocardiogram (x3)
Blood pressure (x3)
Blood draw for complete blood count (x4), chemistry profile (x4), NT-proBNP (x3), cardiac troponin I (x3), serum amyloid A (x3), +/- Total T4 (x1), +/- additional serum for storage (x3)
For questions regarding the clinical trial please email cardiovet@tufts.edu.
If interested in participating in this study, please fill out the Cat Diet Study Survey here to find out if your cat is eligible.
If you believe you have a patient who is eligible for this clinical trial study or you would like additional information from the Clinical Trials Office at the Cummings Veterinary Medical Center, complete a referring physician questionnaire.